Organogenesis Holdings Stock Revenue
| ORGO Stock | USD 4.02 0.05 1.26% |
Organogenesis Holdings fundamentals help investors to digest information that contributes to Organogenesis Holdings' financial success or failures. It also enables traders to predict the movement of Organogenesis Stock. The fundamental analysis module provides a way to measure Organogenesis Holdings' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Organogenesis Holdings stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 433.1 M | 246.9 M |
Organogenesis | Revenue |
Organogenesis Holdings Company Revenue Analysis
Organogenesis Holdings' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Organogenesis Holdings Revenue | 433.14 M |
Most of Organogenesis Holdings' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Organogenesis Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Organogenesis
Projected quarterly revenue analysis of Organogenesis Holdings provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Organogenesis Holdings match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Organogenesis Holdings' stock price.
Organogenesis Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Organogenesis Holdings is extremely important. It helps to project a fair market value of Organogenesis Stock properly, considering its historical fundamentals such as Revenue. Since Organogenesis Holdings' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Organogenesis Holdings' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Organogenesis Holdings' interrelated accounts and indicators.
| 0.35 | 0.35 | 0.32 | 0.5 | 0.24 | ||
| 0.35 | 0.97 | 0.93 | 0.8 | 0.91 | ||
| 0.35 | 0.97 | 0.82 | 0.71 | 0.82 | ||
| 0.32 | 0.93 | 0.82 | 0.83 | 0.96 | ||
| 0.5 | 0.8 | 0.71 | 0.83 | 0.72 | ||
| 0.24 | 0.91 | 0.82 | 0.96 | 0.72 |
Click cells to compare fundamentals
Organogenesis Revenue Historical Pattern
Today, most investors in Organogenesis Holdings Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Organogenesis Holdings' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Organogenesis Holdings revenue as a starting point in their analysis.
Organogenesis Holdings Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Organogenesis Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Organogenesis Holdings reported 433.14 M of revenue. This is 94.32% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 95.41% higher than that of the company.
Organogenesis Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Organogenesis Holdings' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Organogenesis Holdings could also be used in its relative valuation, which is a method of valuing Organogenesis Holdings by comparing valuation metrics of similar companies.Organogenesis Holdings is currently under evaluation in revenue category among its peers.
Organogenesis Holdings Current Valuation Drivers
We derive many important indicators used in calculating different scores of Organogenesis Holdings from analyzing Organogenesis Holdings' financial statements. These drivers represent accounts that assess Organogenesis Holdings' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Organogenesis Holdings' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 446.6M | 811.3M | 1.2B | 349.9M | 536.7M | 726.0M | |
| Enterprise Value | 487.0M | 811.6M | 1.2B | 371.2M | 551.7M | 744.2M |
Organogenesis Holdings ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Organogenesis Holdings' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Organogenesis Holdings' managers, analysts, and investors.Environmental | Governance | Social |
Organogenesis Holdings Institutional Holders
Institutional Holdings refers to the ownership stake in Organogenesis Holdings that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Organogenesis Holdings' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Organogenesis Holdings' value.| Shares | Renaissance Technologies Corp | 2024-09-30 | 817.9 K | Gsa Capital Partners Llp | 2024-09-30 | 773.5 K | D. E. Shaw & Co Lp | 2024-06-30 | 741.9 K | Two Sigma Advisers, Llc | 2024-06-30 | 616.6 K | Northern Trust Corp | 2024-09-30 | 598.9 K | Bank Of America Corp | 2024-06-30 | 496.5 K | Norges Bank | 2024-06-30 | 482.2 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 446.4 K | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 429.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 23.2 M | Soleus Capital Management, L.p. | 2024-06-30 | 11.5 M |
Organogenesis Fundamentals
| Return On Equity | -0.0266 | ||||
| Return On Asset | 0.0164 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 539.66 M | ||||
| Shares Outstanding | 132.58 M | ||||
| Shares Owned By Insiders | 43.44 % | ||||
| Shares Owned By Institutions | 48.28 % | ||||
| Number Of Shares Shorted | 9.79 M | ||||
| Price To Earning | 17.12 X | ||||
| Price To Book | 1.89 X | ||||
| Price To Sales | 1.17 X | ||||
| Revenue | 433.14 M | ||||
| Gross Profit | 345.87 M | ||||
| EBITDA | 36.03 M | ||||
| Net Income | 4.95 M | ||||
| Cash And Equivalents | 113.24 M | ||||
| Cash Per Share | 0.87 X | ||||
| Total Debt | 119.35 M | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 2.62 X | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | 30.92 M | ||||
| Short Ratio | 23.59 X | ||||
| Earnings Per Share | (0.05) X | ||||
| Price To Earnings To Growth | 6.15 X | ||||
| Target Price | 4.7 | ||||
| Number Of Employees | 862 | ||||
| Beta | 1.6 | ||||
| Market Capitalization | 532.96 M | ||||
| Total Asset | 460.02 M | ||||
| Retained Earnings | (40.97 M) | ||||
| Working Capital | 144.53 M | ||||
| Current Asset | 24.47 M | ||||
| Current Liabilities | 23.22 M | ||||
| Net Asset | 460.02 M |
About Organogenesis Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Organogenesis Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Organogenesis Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Organogenesis Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Organogenesis Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.Moving against Organogenesis Stock
| 0.86 | TCHH | Trustcash Holdings | PairCorr |
| 0.79 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.78 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.74 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.73 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.
The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Organogenesis Holdings Piotroski F Score and Organogenesis Holdings Altman Z Score analysis. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.5 | Earnings Share (0.05) | Revenue Per Share 3.446 | Quarterly Revenue Growth 0.061 | Return On Assets 0.0164 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.